Empower asthma patients to know if they have allergies

Order ImmunoCAP™ Specific IgE blood tests this fall

Give asthma patients the full picture of what is or isn’t contributing to symptoms

Take action this fall in helping to prevent asthma exacerbations

General practitioners and pediatrician know best that patients with asthma are fine until they aren’t. Underlying inflammation, exposure to allergens to which the patient is sensitized and viral infections that run rampant in the fall can be a recipe for exacerbations.¹

Get it right the first time

Dust mites, mold and pet dander are common indoor allergens patients are exposed to as they spend more time inside during the cooler months. But just because they are exposed doesn’t mean they’re sensitized.² You have a tool in primary care that can help patients better understand what is or is not contributing to their asthma symptoms.

ImmunoCAP™ Specific IgE Blood Testing – a tool to equip patients to control inflammation

Use symptoms, history and ImmunoCAP™ Specific IgE blood testing – available through the lab – to identify which allergic sensitizations your patients with asthma may have, especially
when you plan to refer your patient to a specialist.

How can specific IgE test results help change patient management?2

According to experts, compelling reasons to incorporate specific IgE testing into asthma management include:

  • Can guide clinical precision medicine for chronic airway disease in individual patients.
  • Negative allergy test results prompt a search for other causes of symptoms.
  • Known aeroallergen sensitization of environmental remediation advice and allergen immunotherapy (AIT) when appropriate.
  • Address common patient concerns about allergy, predicting exacerbations and response to therapies, and possibly increase compliance with therapy.
  • Positive allergy test results can be considered as one of the referral criteria for specialist care.

1. Murray CS, et al. Thorax. 2006;61:376-82.
2. Casale T, et al. J Allergy Clin Immunol Pract. 2020;8:2526-3